Skip to main content
Top
Published in: Cancer Cell International 1/2018

Open Access 01-12-2018 | Primary Research

miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L

Authors: Jie Hao, Xin Jin, Yan Shi, Hong Zhang

Published in: Cancer Cell International | Issue 1/2018

Login to get access

Abstract

Background

Lacrimal adenoid cystic carcinoma (LACC) is one of the most common malignancies that affects lacrimal gland. MicroRNAs are known to play a crucial role as oncogenes or tumor suppressors. Specifically, miR-93 has been reported to play a crucial role in colorectal, breast, pancreatic, lung cancer and hepatocellular carcinoma. However, the role of miR-93 in LACC and the potential molecular mechanisms involved remain unknown. Therefore, we took the challenge to determine the involvement of miR-93 in the LACC by targeting BRMS1L.

Method

A total of 5 adenoid cystic carcinoma (ACC) of lacrimal gland patient tissues and their plasma were examined. Three normal lacrimal glands and three normal serums were collected as a control group. After surgical resection, the specimens were preserved in liquid nitrogen and stored at − 80 °C until RNA extraction. Afterwards, LACC cells with miR-93-5p overexpression were subjected to qRT-PCR and western blot for epithelial–mesenchymal transition (EMT) markers levels. Ability of LACC cell migration, invasion, proliferation and apoptosis was examined by wounded healing, transwell, CCK-8 and apoptosis assays. Afterwards, TargetScan was used to predict putative targets of miR-93-5p. Then, the examination was performed whether miR-93-5p targets BRMS1L by the use of luciferase reporter assays and western blotting. Finally, immunohistochemical staining was sone and all the images were taken using a microscope (Nikon, Tokyo).

Results

Our results showed that miR-93 was overexpressed in tissues and plasma of LACC patients compared to healthy controls. MiR-93 downregulated E-cadherin expression while increasing N-cadherin expression and significantly inhibited luciferase activity. Furthermore, western blotting results confirmed that miR-93-5p could inhibit BRMS1L expression. The BRMS1L staining in LACC tissues was weaker than in normal controls. In addition, miR-93-5p revealed a reverse correlation with the expression of BRMS1L. In addition, significant upregulation of E-cadherin and downregulation of N-cadherin were found when LACC cells were transfected with BRMS1L. Finally, miR-93-5p significantly enhanced TOP/FOP luciferase activity. Upregulation of BRMS1L reduced TOP/FOP luciferase activity while further overexpression of miR-93-5p could not rescue Wnt signaling activity.

Conclusions

Our findings report that miR-93 promotes LACC cell migration, invasion, and proliferation via targeting downregulation of BRMS1L through regulation of Wnt signaling pathway.
Appendix
Available only for authorised users
Literature
1.
go back to reference Weis E, et al. Epithelial lacrimal gland tumors: pathologic classification and current understanding. Arch Ophthalmol. 2009;127(8):1016–28.CrossRefPubMed Weis E, et al. Epithelial lacrimal gland tumors: pathologic classification and current understanding. Arch Ophthalmol. 2009;127(8):1016–28.CrossRefPubMed
2.
go back to reference Bernardini FP, Devoto MH, Croxatto JO. Epithelial tumors of the lacrimal gland: an update. Curr Opin Ophthalmol. 2008;19(5):409–13.CrossRefPubMed Bernardini FP, Devoto MH, Croxatto JO. Epithelial tumors of the lacrimal gland: an update. Curr Opin Ophthalmol. 2008;19(5):409–13.CrossRefPubMed
3.
go back to reference von Holstein SL, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology. 2013;120(10):2130–8.CrossRef von Holstein SL, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology. 2013;120(10):2130–8.CrossRef
4.
go back to reference Esmaeli B, et al. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg. 2004;20(1):22–6.CrossRefPubMed Esmaeli B, et al. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg. 2004;20(1):22–6.CrossRefPubMed
5.
go back to reference Tse DT, et al. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol. 2006;141(1):44–53.CrossRefPubMed Tse DT, et al. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol. 2006;141(1):44–53.CrossRefPubMed
6.
go back to reference Mallen-St Clair J, et al. Epidemiology and treatment of lacrimal gland tumors: a population-based cohort analysis. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1110–6.CrossRefPubMed Mallen-St Clair J, et al. Epidemiology and treatment of lacrimal gland tumors: a population-based cohort analysis. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1110–6.CrossRefPubMed
7.
go back to reference Jang SY, et al. Neoadjuvant intra-arterial chemotherapy in patients with primary lacrimal adenoid cystic carcinoma. Cancer Imaging. 2014;14:19.PubMedPubMedCentral Jang SY, et al. Neoadjuvant intra-arterial chemotherapy in patients with primary lacrimal adenoid cystic carcinoma. Cancer Imaging. 2014;14:19.PubMedPubMedCentral
8.
go back to reference Zhou Q, et al. High-grade transformation in adenoid cystic carcinoma: a clinicopathologic study. Zhonghua Bing Li Xue Za Zhi. 2013;42(2):106–10.PubMed Zhou Q, et al. High-grade transformation in adenoid cystic carcinoma: a clinicopathologic study. Zhonghua Bing Li Xue Za Zhi. 2013;42(2):106–10.PubMed
9.
go back to reference Zheng H, et al. MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of beta-catenin signaling. Oncotarget. 2016;7(4):4647–63.PubMed Zheng H, et al. MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of beta-catenin signaling. Oncotarget. 2016;7(4):4647–63.PubMed
10.
go back to reference Chen TY, et al. Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement. Eye (Lond). 2017;31(5):720–5.CrossRef Chen TY, et al. Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement. Eye (Lond). 2017;31(5):720–5.CrossRef
11.
go back to reference Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol. 1998;116(3):315–21.CrossRefPubMed Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol. 1998;116(3):315–21.CrossRefPubMed
12.
go back to reference Falcone MM, et al. Adenoid cystic carcinoma of the lacrimal gland in a 14-year-old male. Orbit. 2017;36 (6):448–51.CrossRefPubMed Falcone MM, et al. Adenoid cystic carcinoma of the lacrimal gland in a 14-year-old male. Orbit. 2017;36 (6):448–51.CrossRefPubMed
13.
go back to reference Tellado MV, et al. Adenoid cystic carcinomas of the lacrimal gland in childhood and adolescence. Ophthalmology. 1997;104(10):1622–5.CrossRefPubMed Tellado MV, et al. Adenoid cystic carcinomas of the lacrimal gland in childhood and adolescence. Ophthalmology. 1997;104(10):1622–5.CrossRefPubMed
14.
go back to reference Sestini S, et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget. 2015;6(32):32868–77.CrossRefPubMedPubMedCentral Sestini S, et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget. 2015;6(32):32868–77.CrossRefPubMedPubMedCentral
15.
go back to reference Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′UTR as in the 3′UTR. Proc Natl Acad Sci USA. 2007;104(23):9667–72.CrossRefPubMedPubMedCentral Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′UTR as in the 3′UTR. Proc Natl Acad Sci USA. 2007;104(23):9667–72.CrossRefPubMedPubMedCentral
16.
go back to reference Zhang MX, et al. miR-24-3p suppresses malignant behavior of lacrimal adenoid cystic carcinoma by targeting PRKCH to regulate p53/p21 pathway. PLoS ONE. 2016;11(6):e0158433.CrossRefPubMedPubMedCentral Zhang MX, et al. miR-24-3p suppresses malignant behavior of lacrimal adenoid cystic carcinoma by targeting PRKCH to regulate p53/p21 pathway. PLoS ONE. 2016;11(6):e0158433.CrossRefPubMedPubMedCentral
18.
go back to reference Fang L, et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene. 2011;30(7):806–21.CrossRefPubMed Fang L, et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene. 2011;30(7):806–21.CrossRefPubMed
19.
go back to reference Fabbri E, et al. MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells. Oncol Rep. 2016;35(5):2866–72.CrossRefPubMed Fabbri E, et al. MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells. Oncol Rep. 2016;35(5):2866–72.CrossRefPubMed
20.
21.
go back to reference Edmonds MD, et al. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer. 2009;125(8):1778–85.CrossRefPubMedPubMedCentral Edmonds MD, et al. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer. 2009;125(8):1778–85.CrossRefPubMedPubMedCentral
22.
go back to reference Phadke PA, et al. BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol. 2008;172(3):809–17.CrossRefPubMedPubMedCentral Phadke PA, et al. BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol. 2008;172(3):809–17.CrossRefPubMedPubMedCentral
23.
go back to reference Shevde LA, et al. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res. 2002;273(2):229–39.CrossRefPubMed Shevde LA, et al. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res. 2002;273(2):229–39.CrossRefPubMed
24.
go back to reference Smith PW, et al. Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Lett. 2009;276(2):196–203.CrossRefPubMed Smith PW, et al. Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Lett. 2009;276(2):196–203.CrossRefPubMed
25.
go back to reference Lyu J, et al. The cultivation and identification of lacrimal gland adenoid cystic cancer stem cells. Zhonghua Yan Ke Za Zhi. 2015;51(10):762–7.PubMed Lyu J, et al. The cultivation and identification of lacrimal gland adenoid cystic cancer stem cells. Zhonghua Yan Ke Za Zhi. 2015;51(10):762–7.PubMed
26.
go back to reference Lin T, et al. Establishment and characterization of a cell line from human adenoid cystic carcinoma of the lacrimal glands and a nude mouse transplantable model. Oncol Rep. 2015;33(6):2797–806.CrossRefPubMed Lin T, et al. Establishment and characterization of a cell line from human adenoid cystic carcinoma of the lacrimal glands and a nude mouse transplantable model. Oncol Rep. 2015;33(6):2797–806.CrossRefPubMed
27.
go back to reference Ma DH, et al. miR-93-5p/IFNAR1 axis promotes gastric cancer metastasis through activating the STAT3 signaling pathway. Cancer Lett. 2017;408:23–32.CrossRefPubMed Ma DH, et al. miR-93-5p/IFNAR1 axis promotes gastric cancer metastasis through activating the STAT3 signaling pathway. Cancer Lett. 2017;408:23–32.CrossRefPubMed
28.
go back to reference Li L, et al. MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway. Gene. 2017;641:240–7.CrossRefPubMed Li L, et al. MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway. Gene. 2017;641:240–7.CrossRefPubMed
29.
go back to reference Xiang Y, et al. MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3. Exp Cell Res. 2017;357(1):135–44.CrossRefPubMed Xiang Y, et al. MiR-93-5p inhibits the EMT of breast cancer cells via targeting MKL-1 and STAT3. Exp Cell Res. 2017;357(1):135–44.CrossRefPubMed
30.
31.
go back to reference Gong C, et al. BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. Nat Commun. 2014;5:5406.CrossRefPubMed Gong C, et al. BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. Nat Commun. 2014;5:5406.CrossRefPubMed
35.
go back to reference Wang L, et al. MiR-573 inhibits prostate cancer metastasis by regulating epithelial–mesenchymal transition. Oncotarget. 2015;6(34):35978–90.PubMedPubMedCentral Wang L, et al. MiR-573 inhibits prostate cancer metastasis by regulating epithelial–mesenchymal transition. Oncotarget. 2015;6(34):35978–90.PubMedPubMedCentral
36.
go back to reference Yang IP, et al. MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis 2012;33(8):1522–30.CrossRefPubMed Yang IP, et al. MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis 2012;33(8):1522–30.CrossRefPubMed
37.
38.
go back to reference Long J, et al. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem. 2010;285(30):23457–65.CrossRefPubMedPubMedCentral Long J, et al. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem. 2010;285(30):23457–65.CrossRefPubMedPubMedCentral
39.
go back to reference Tang Q, et al. MicroRNA-93 suppress colorectal cancer development via Wnt/beta-catenin pathway downregulating. Tumour Biol. 2015;36(3):1701–10.CrossRefPubMed Tang Q, et al. MicroRNA-93 suppress colorectal cancer development via Wnt/beta-catenin pathway downregulating. Tumour Biol. 2015;36(3):1701–10.CrossRefPubMed
Metadata
Title
miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L
Authors
Jie Hao
Xin Jin
Yan Shi
Hong Zhang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-018-0552-9

Other articles of this Issue 1/2018

Cancer Cell International 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine